Treatment of COPD: From pharmacological to instrumental therapies

European Respiratory Review

Volumn 19, Issue 115, 2010, Pages 7-23

  Alifano, M ^a   Cuvelier, A ^b,c   Delage, A ^d   Roche, N ^a   Lamia, B ^b,c   Molano, L C ^b,c   Couderc, L J ^a,e   Marquette, C H ^d   Devillier, P ^f  

^a HÔTEL DIEU   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c CHU de Rouen   (France)

^d UNIVERSITY HOSPITAL OF NICE   (France)

^e LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^f UPRES EA 220   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; INDACATEROL; MUSCARINIC RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; ZEPHYR VALVE SYSTEM;

ADD ON THERAPY; AMBULATORY CARE; ARTICLE; ARTIFICIAL VENTILATION; BULLECTOMY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG POTENCY; EMPHYSEMA; ENDOSCOPIC SURGERY; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; HEALTH PROGRAM; HIGH RISK PATIENT; HUMAN; HYPERINFLATION; INFECTION RISK; LONG TERM CARE; LUNG FUNCTION; LUNG RESECTION; LUNG SURGERY; MORTALITY; NON INVASIVE PROCEDURE; OXYGEN THERAPY; PATIENT COMPLIANCE; PATIENT SELECTION; PNEUMONIA; PRACTICE GUIDELINE; PULMONARY REHABILITATION; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SURGICAL TECHNIQUE; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; VALVE;

EID: 77649210255     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.00008009     Document Type: Article

References (149)

1. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555.
2. Herland K, Akselsen JP, Skjonsberg OH, et al. How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease? Respir Med 2005; 99: 11-19.
3. Beasley R, Weatherall M, Travers J, et al. Time to define the disorders of the syndrome of COPD. Lancet 2009; 374: 670-672.
4. Puhan MA, Schüneman HJ. How to increase the value of randomised trials in COPD research. Eur Respir J 2009; 34: 552-558.
5. Halpin DMG, Tashkin DP. Defining disease modification in chronic obstructive Pulmonary disease. COPD 2009; 6: 211-225.
6. Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 2006; 27: 547-555.
7. Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
8. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332-338.
9. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
10. Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled clinical trial. Lancet 2009; 374: 1171-1178.
11. Miravitlles M, Anzueto A. Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studies. Int J COPD 2009; 4: 185-201.
12. Keene ON, Vestbo J, Anderson JA, et al. Methods for therapeutic trials in COPD: lessons from the TORCH trial. Eur Respir J 2009; 34: 1018-1023.
13. Beeh KM, Hederer B, Glaab T, et al. Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. Int J COPD 2009; 4: 119-125.
14. Anzueto A, Tashkin D, Menjorge S, et al. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther 2005; 18: 75-81.
15. Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 948-955.
16. O'Donnell DE, Voduc N, Fitzpatrick M, et al. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004; 24: 86-94.
17. O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832-840.
18. Postma DS, Calverley P. Inhaled corticosteroids in COPD: a case in favour. Eur Respir J 2009; 34: 10-12.
19. Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. Eur Respir J 2009; 34: 13-16.
20. Jones PW, Willits LR, Burge PS, et al. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003; 21: 68-73.
21. Puhan MA, Bachmann L, Kleijnen J, et al. Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network analysis. BMC Medicine 2009; 7: 2.
22. Wedzicha JA, Calverlet PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177: 19-26.
23. Rodrigo J, Castro-Rodriguez JA, Plaza V. Safety and efficacy of combined long-acting b2-agonists and inhaled corticosteroids vs long-acting b2-agonists monotherapy for stable COPD. Chest 2009; 136: 1029-1038.
24. O'Donnell DE, Sciurba F, Celli B, et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 2006; 130: 647-656.
25. Nava S, Compagnoni ML. Controlled short-term trial of fluticasone propionate in ventilator-dependent patients with COPD. Chest 2000; 118: 990-999.
26. John M, Bosse S, Oltmanns U, et al. Effects of inhaled HFA beclomethasone on pulmonary function and symptoms in patients with chronic obstructive pulmonary disease. Respir Med 2005; 99: 1418-1424.
27. Crim C, Calverley PMA, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009; 34: 641-647.
28. Sin DD, Tashkin D, Zhang X, et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009; 374: 712-719.
29. Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease. JAMA 2008; 300: 2407-2416.
30. Singh D, Brooks J, Hagan G, et al. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual component in moderate to severe COPD. Thorax 2008; 63: 592-598.
31. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146: 545-555.
32. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 741-750.
33. Zuwallack RL, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001; 119: 1661-1670.
34. Cosio BG, Soriano JB. Theophylline again? Reasons for believing. Eur Respir J 2009; 34: 5-6.
35. Cosio BG, Iglesias A, Rios A, et al. Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD. Thorax 2009; 64: 424-429.
36. Calverley PMA, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374: 685-694.
37. Fabbri M, Calverley PMA, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials. Lancet 2009; 374: 695-703.
38. O'Byrne PM, Gauvreau G. Phosphodiesterase inhibition in COPD. Lancet 2009; 374: 665-667.
39. Seemungal TAR, Wedzicha JA. Integrated care: a new model for COPD management? Eur Respir J 2006; 28: 4-6.
40. Restrepo RD, Alvarez MT, Wittnebel LD, et al. Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis 2008; 3: 371-384.
41. Polkey MI, Rabe KF. Chicken or egg: physical activity in COPD revisited. Eur Respir J 2009; 33: 227-229.
42. Garcia-Aymerich J, Lange P, Serra I, et al. Time-dependent confounding in the study of the effects of regular physical activity in chronic obstructive pulmonary disease: an application of the marginal structural model. Ann Epidemiol 2008; 18: 775-783.
43. Garcia-Aymerich J, Serra I, Gomez FP, et al. Physical activity and clinical and functional status in COPD. Chest 2009; 136: 62-70.
44. Garcia-Aymerich J, Hernandez C, Alonso A, et al. Effects of an integrated care intervention on risk factors of COPD readmission. Respir Med 2007; 101: 1462-1469.
45. Vestbo J, Anderson JA, Calverley PMA, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax 2009; 64: 939-943.
46. Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur Respir J 2009; 34: 757-769.
47. McKinstry B, Pinnock H, Sheikh A. Telemedicine for management of patients with COPD. Lancet 2009; 374: 672-673.
48. Yasothan U, Kar S. Therapies for COPD. Nat Rev Drug Dis 2008; 7: 285-286.
49. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31: 416-469.
50. European Medicines Agency. Committee for medicinal products for human use (CHMP). Concept paper on the need for revision of the points to consider on clinical investigation of medicinal products in the chronic treatments of patients with COPD. EMEA/CHMP/EWP/8197/2009. www.ema.europa.eu/pdfs/human/ewp/ 819709en.pdf
51. Miravitlles M, Brosa M, Velasco M, et al. An economic analysis of pharmacological treatment of COPD in Spain. Respir Med 2009; 103: 714-721.
52. Briggs AH, Glick HA, Lozano-Ortega G, et al. Is treatment with ICS and LABA cost-effective for COPD? Multionational economic analysis of the TORCH study. Eur Respir J 2010; 35: 532-539.
53. Najafdeh M, Marra CA, Sadatsafavi M, et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax 2008; 63: 962-967.
54. Weatherall M, Travers J, Shirtcliffe P, et al. Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J 2009; 34: 812-818.
55. Burgel PR, Nesme-Meyer P, Chanez P, et al. Initiatives BPCO Scientific Committee. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009; 135: 975-982.
56. Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J 2008; 31: 869-873.
57. Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with chronic obstructuve pulmonary disease: the updated BODE index and the ADO index. Lancet 2009; 374: 704-711.
58. Cranston JM, Crockett AJ, Moss JR, et al. Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; 4: CD001744.
59. Croxton TL, Bailey WC. Long-term oxygen treatment in chronic obstructive pulmonary disease: recommendations for future research. An NHLBI Workshop Report. Am J Respir Crit Care Med 2006; 174: 373-378.
60. Bradley JM, Lasserson T, Elborn S, et al. A systematic review of randomized controlled trials examining the short-term benefit of ambulatory oxygen in COPD. Chest 2007; 131: 278-285.
61. Sandland CJ, Morgan MD, Singh SJ. Patterns of domestic activity and ambulatory oxygen usage in COPD. Chest 2008; 134: 753-760.
62. Nonoyama ML, Brooks D, Guyatt GH, et al. Ambulatory gas usage in patients with chronic obstructive pulmonary disease and exertional hypoxemia. J Cardiopulm Rehabil Prev 2008; 28: 323-329.
63. Nonoyama ML, Brooks D, Guyatt GH, et al. Effect of oxygen on health quality of life in patients with chronic obstructive pulmonary disease with transient exertional hypoxemia. Am J Respir Crit Care Med 2007; 176: 343-349.
64. Quantrill SJ, White R, Crawford A, et al. Short burst oxygen therapy after activities of daily living in the home in chronic obstructive pulmonary disease. Thorax 2007; 62: 702-705.
65. Nasilowski J, Przybylowski T, Zielinski J, et al. Comparing supplementary oxygen benefits from a portable oxygen concentrator and a liquid oxygen portable device during a walk test in COPD patients on long-term oxygen therapy. Respir Med 2008; 102: 1021-1025.
66. Hirche TO, Born T, Jungblut S, et al. Oxygen generation by combined electrolysis and fuel-cell technology: clinical use in COPD patients requiring long time oxygen therapy. Eur J Med Res 2008; 13: 451-458.
67. Lobbi MG, Simonds AK, Dickinson RJ. Oximetry feedback flow control simulation for oxygen therapy. J Clin Monit Comput 2007; 21: 115-123.
68. Ekstrom M, Franklin KA, Strom KE. Increased relative mortality in women with severe oxygen-dependent chronic obstructive pulmonary disease. Chest 2010; 137: 31-36.
69. Coleta KD, Silveira LV, Lima DF, et al. Predictors of first-year survival in patients with advanced COPD treated using longterm oxygen therapy. Respir Med 2008; 102: 512-518.
70. Fremault A, Silva M, Beaucage F, et al. Inspired fraction of carbon dioxide in oxygen supply to chronic pulmonary disease. Respir Med 2008; 102: 1827-1829.
71. Rizzi M, Grassi M, Pecis M, et al. A specific home care program improves the survival of patients with chronic obstructive pulmonary disease receiving long term oxygen therapy. Arch Phys Med Rehabil 2009; 90: 395-401.
72. Vitacca M, Bianchi L, Guerra A, et al. Tele-assistance in chronic respiratory failure patients: a randomised clinical trial. Eur Respir J 2009; 33: 411-418.
73. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31: 416-469.
74. Kolodziej MA, Jensen L, Rowe B, et al. Systematic review of noninvasive positive pressure ventilation in severe stable COPD. Eur Respir J 2007; 30: 293-306.
75. McEvoy RD, Pierce RJ, Hillman D, et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax 2009; 64: 561-566.
76. Budweiser S, Jorres RA, Riedl T, et al. Predictors of survival in COPD patients with chronic hypercapnic respiratory failure receiving noninvasive home ventilation. Chest 2007; 131: 1650-1658.
77. Nickol AH, Hart N, Hopkinson NS, et al. Mechanisms of improvement of respiratory failure in patients with COPD treated with NIV. Int J Chron Obstruct Pulmon Dis 2008; 3: 453-462.
78. Windisch W, Kostić S, Dreher M, et al. Outcome of patients with stable COPD receiving controlled noninvasive positive pressure ventilation aimed at a maximal reduction of Pa(CO2). Chest 2005; 128: 657-662.
79. Windisch W, Haenel M, Storre JH, et al. High-intensity noninvasive positive pressure ventilation for stable hypercapnic COPD. Int J Med Sci 2009; 6: 72-76.
80. Kohnlein T, Schonheit-Kenn U, Winterkamp S, et al. Noninvasive ventilation in pulmonary rehabilitation of COPD patients. Respir Med 2009; 103: 1329-1336.
81. Duiverman ML, Wempe JB, Bladder G, et al. Nocturnal noninvasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax 2008; 63: 1052-1057.
82. Dreher M, Storre JH, Windisch W. Noninvasive ventilation during walking in patients with severe COPD: a randomised cross-over trial. Eur Respir J 2007; 29: 930-936.
83. Dreher M, Doncheva E, Schwoerer A, et al. preserving oxygenation during walking in severe chronic obstructive pulmonary disease: noninvasive ventilation versus oxygen therapy. Respiration 2009; 78: 154-160.
84. Tsolaki V, Pastaka C, Karetsi E, et al. One-year non-invasive ventilation in chronic hypercapnic COPD: effect on quality of life. Respir Med 2008; 102: 904-911.
85. Windisch W. Impact of home mechanical ventilation on health-related quality of life. Eur Respir J 2008; 32: 1328-1336.
86. The definition of emphysema. Report of a National Heart Lung and Blood Institute, Division of Lung Diseases workshop. Am Rev Respir Dis 1985; 132: 182-185.
87. Suki B, Lutchen KR, Ingenito EP. On the progressive nature of emphysema: roles of proteases, inflammation, and mechanical forces. Am J Respir Crit Care Med 2003; 168: 516-521.
88. Celli BR. Update on the management of COPD. Chest 2008; 133: 1451-1462.
89. Deslauriers J. History of surgery for emphysema. Semin Thorac Cardiovasc Surg 1996; 8: 43-51.
90. Connolly JE, Wilson A. The current status of surgery for bullous emphysema. J Thorac Cardiovasc Surg 1989; 97: 351-361.
91. Greenberg JA, Singhal S, Kaiser LR. Giant bullous lung disease: evaluation, selection, techniques, and outcomes. Chest Surg Clin N Am 2003; 13: 631-649.
92. Mehran RJ, Deslauriers J. Indications for surgery and patient work-up for bullectomy. Chest Surg Clin N Am 1995; 5: 717-734.
93. Schipper PH, Meyers BF. Surgery for bullous disease. In: Patterson GA, Cooper JD, Deslauriers J, et al., eds. Pearson's Thoracic and Esophageal Surgery. 3rd Edn. Philadelphia, Churchill Livingstone, 2008: pp. 631-652.
94. Gunstensen J, McCormack RJM. The surgical management of bullous emphysema. J Thorac Cardiovasc Surg 1973; 65: 920-925.
95. Lopez-Majano V, Kieffer RF Jr, Marine DN, et al. Pulmonary resection in bullous disease. Am Rev Respir Dis 1969; 99: 554-564. 96 Benditt JO. Surgical options for patients with COPD: sorting out the choices. Respir Care 2006; 51: 173-182.
96. Morgan MD, Denison DM, Strickland B. Value of computed tomography for selecting patients with bullous lung disease for surgery. Thorax 1986; 41: 855-862.
97. Klein RC, Kazemi H, Strieder DJ. Regional lung function in obstructive and bullous emphysema. South Med J 1972; 65: 721-726.
98. Nakahara K, Nakaoka K, Ohno K, et al. Functional indications for bullectomy of giant bulla. Ann Thorac Surg 1983; 35: 480-487.
99. Vishnevsky AA, Nickoladze GD. One-stage operation for bilateral bullous lung disease. J Thorac Cardiovasc Surg 1990; 99: 30-34.
100. Laros CD, Gelissen HJ, Bergstein PG, et al. Bullectomy for giant bullae in emphysema. J Thorac Cardiovasc Surg 1986; 91: 63-70.
101. FitzGerald MX, Keelan PJ, Cugell DW, et al. Long-term results of surgery for bullous emphysema. J Thorac Cardiovasc Surg 1974; 68: 566-587.
102. Shah SS, Goldstraw P. Surgical treatment of bullous emphysema: experience with the Brompton technique. Ann Thorac Surg 1994; 58: 1452-1456.
103. Schipper PH, Meyers BF, Battafarano RJ, et al. Outcomes after resection of giant emphysematous bullae. Ann Thorac Surg. 2004; 78: 976-982.
104. Snider GL. Reduction pneumoplasty for giant bullous emphysema. Implications for surgical treatment of nonbullous emphysema. Chest 1996; 109: 540-548.
105. Palla A, Desideri M, Rossi G, et al. Elective surgery for giant bullous emphysema: a 5-year clinical and functional follow-up. Chest. 2005; 128: 2043-2050.
106. Vejlsted H, Halkier E. Surgical improvement of patients with pulmonary insufficiency due to localized bullous emphysema or giant cysts. Thorac Cardiovasc Surg. 1985; 33: 335-336.
107. Ohta M, Nakahara K, Yasumitsu T, et al. Prediction of postoperative performance status in patients with giant bulla. Chest 1992; 101: 668-673.
108. De Giacomo T, Venuta F, Rendina EA, et al. Video-assisted thoracoscopic treatment of giant bullae associated with emphysema. Eur J Cardiothorac Surg 1999; 15: 753-756.
109. Brantigan OC. Surgical treatment of pulmonary emphysema. MD State Med J 1957; 6: 409-414.
110. Cooper JD, Trulock EP, Triantafillou AN, et al. Bilateral pneumectomy (volume reduction) for chronic obstructive pulmonary disease. J Thorac Cardiovasc Surg 1995; 109: 106-116.
111. Rationale and design of the National Emphysema Treatment Trial (NETT): A prospective randomized trial of lung volume reduction surgery. J Thorac Cardiovasc Surg 1999; 118: 518-528.
112. Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348: 2059-2073.
113. Ciccone AM, Meyers BF, Guthrie TJ, et al. Long-term outcome of bilateral lung volume reduction in 250 consecutive patients with emphysema. J Thorac Cardiovasc Surg 2003; 125: 513-525.
114. National Emphysema Treatment Trial Research Group. Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med 2001; 345: 1075-1083.
115. Washko GR, Fan VS, Ramsey SD, et al. The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008; 177: 164-169.
116. Snyder ML, Goss CH, Neradilek B, et al. Changes in arterial oxygenation and self-reported oxygen use after lung volume reduction surgery. Am J Respir Crit Care Med 2008; 178: 339-345.
117. Drazen JM, Epstein AM. Guidance concerning surgery for emphysema. N Engl J Med 2003; 348: 2134-2136.
118. Ware JH. The National Emphysema Treatment Trial - how strong is the evidence? N Engl J Med 2003; 348: 2055-2056.
119. Toma TP, Hopkinson NS, Polkey MI, et al. Endobronchial volume reduction: a myth or a marvel? Sem Respir Crit Care Med 2004; 25: 399-404.
120. Toma TP. Lung-volume reduction. Lancet 2001; 357: 1621.
121. Terry PB, Traystman RJ, Newball HH, et al. Collateral ventilation in man. N Engl J Med 1978; 298: 10-15.
122. Hopkinson NS, Toma TP, Hansell DM, et al. Effect of bronchoscopic lung volume reduction on dynamic hyperinflation and exercise during emphysema. Am J Respir Crit Care Med 2005; 171: 453-460.
123. Fessler HE. Collateral ventilation, the bane of bronchoscopic volume reduction. Am J Respir Crit Care Med 2005; 171: 423-424.
124. Watanabe Y, Matsuo K, Tamaoki A, et al. Bronchial occlusion with endobronchial watanabe spigot. J Bronchol 2003; 10: 264-267.
125. Macklem PT. Collateral ventilation. N Engl J Med 1978; 298: 49-50.
126. Lausberg HF, Chino K, Patterson A, et al. Bronchial fenestration improves expiratory flow in emphysematous human lungs. Ann Thorac Surg 2003; 75: 393-398.
127. Brenner M, Hanna NM, Mina-Araghi R, et al. Innovative approaches to lung volume reduction for emphysema. Chest 2004; 126: 238-248.
128. Venuta F, De Giacomo T, Rendina EA, et al. Bronchoscopic lung-volume reduction with one-way valves in patients with heterogenous emphysema. Ann Thorac Surg 2005; 79: 411-417.
129. Snell GI, Holsworth L, Borrill ZL, et al. The potential for bronchoscopic lung volume reduction using bronchial prostheses. A pilot study. Chest 2003; 124: 1073-1080.
130. Toma TP, Hopkinson NS, Hillier J, et al. Bronchoscopic volume reduction with valve implants in patients with severe emphysema. Lancet 2002; 361: 931-933.
131. Wan IY, Toma TP, Geddes DM, et al. Bronchoscopic lung volume reduction for end-stage emphysema. Report on the first 98 patients. Chest 2006; 129: 518-526.
132. De Oliveira HG, Macedo-Neto AV, John AB, et al. Transbronchoscopic pulmonary emphysema treatment. 1-month to 24-month endoscopic follow-up. Chest 2006; 130: 190-199.
133. Yim AP, Hwong TM, Lee TW, et al. Early results of endoscopic lung volume reduction for emphysema. J Thorac Cardiovasc Surg 2004; 127: 1564-1573.
134. Strange C, Herth FJ, Kovitz KL, et al. Design of the endobronchial valve for Emphysema Palliation Trial (VENT): a non-surgical method of lung volume reduction. BMC Pulmonary Medicine 2007; 7: 10.
135. Leroy S, Marquette CH. [VENT: International Study of bronchoscopic lung volume reduction as a palliative treatment for emphysema]. Rev Mal Respir 2004; 21: 1144-1152.
136. Ingenito EP, Wood DE, Utz JP. Bronchoscopic lung volume reduction in severe emphysema. Proc Am Thor Soc 2008; 5: 454-460.
137. Wood DE, McKenna RJ, Yusen RD, et al. A multicenter trial of an intrabronchial valve for treatment of severe emphysema. J Thorac Cardiovasc Surg 2007; 133: 65-73.
138. Macklem PT, Cardoso P, Snell G, et al. Airway bypass: a new treatment for emphysema. Proc Am Thor Soc 2006; 3: A726.
139. Choong CK, Macklem PT, Pierce JA, et al. Airway bypass improves the mechanical properties of explanted emphysematous lungs. Am J Resp Crit Care Med 2008; 178: 902-905.
140. Lausberg HF, Chino K, Patterson A, et al. Bronchial fenestration improves expiratory flow in emphysematous human lungs. Ann Thorac Surg 2003; 75: 393-398.
141. Ingenito EP, Berger RL, Henderson AC, et al. Bronchoscopic lung volume reduction using tissue engineering principles. Am J Respir Crit Care Med 2003; 167: 771-778.
142. Reilly J, Washko G, Pinto-Plata V, et al. Biological lung volume reduction: a new bronchoscopic therapy for advanced emphysema. Chest 2007; 131: 1108-1113.
143. Criner GJ, Pinto-Plata V, Strange C, et al. Biologic lung volume reduction (BioLVR) in advanced upper lobe emphysema: phase 2 results. Am J Resp Crit Care Med 2009; 179: 791-798.
144. Coxson HO, Fauerbach PV, Storness-Bliss C, et al. Computed tomography assessment of lung volume changes after bronchial valve treatment. Eur Respir J 2008; 32: 1443-1450.
145. Sciurba FC, Ernst A, Herth F, et al. Effect of bronchoscopically implanted endobronchial valves on lobar volumes, lung function and exercise tolerance in patients with severe emphysema. N Engl J Med 2010; (In press).
146. Aljuri N, Freitag L. Validation and pilot clinical study of a new bronchoscopic method to measure collateral ventilation before endobronchial lung volume reduction. J Appl Physiol 2009; 106: 755-756.
147. Toma TP, Hopkinson J, Hillier J, et al. Effect of unilateral total lobar occlusion with bronchoscopic valve implants in patients with severe heterogenous emphysema. Am J Respir Crit Care Med 2004; 165: A576.
148. Garcia-Rio F, Lores V, Mediano O, et al. Daily physical activity in patients with chronic obstructive pulmonary disease is mainly associated with dynamic hyperinflation. Am J Respir Crit Care Med 2009; 180: 506-512.
149. Roche N. Activity limitation: a major consequence of dyspnoea in COPD. Eur Respir Rev 2009; 18: 54-57.